Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 720M 617M 576M 528M 992M 68.94B 1.01B 6.83B 2.66B 34.55B 2.71B 2.65B 114B P/E 2026 *
3.56x
P/E 2027 * 3.46x
Enterprise Value 720M 617M 576M 528M 992M 68.94B 1.01B 6.83B 2.66B 34.55B 2.71B 2.65B 114B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.46x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day-5.05%
1 week+1.47%
Current month-2.13%
1 month+7.53%
3 months+5.61%
6 months+4.55%
Current year+22.85%
1 week 3.96
Extreme 3.96
4.49
1 month 3.55
Extreme 3.55
4.59
Current year 2.95
Extreme 2.95
5.78
1 year 1.01
Extreme 1.01
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 20/07/2026
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap.
20/07/26 Free

Chief Technology Officer

137,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-127,890 0.0777%
23/02/26 Sell

Chief Executive Officer

198,283 0.1219%
Change 5-day change 1-year change 3-year change Capi.($)
-5.05%+1.47%+276.36%-57.41% 720M
-2.11%+9.92%+75.99%+35.89% 376B
-0.22%-1.39%+24.43%-13.20% 70.12B
-1.39%+5.41%+49.19%+148.99% 12.21B
+1.37%+1.27%-1.11%+2.28% 8.55B
+1.41%-1.93%-11.46%0.00% 4.8B
+4.77%+0.36%-26.71%+19.47% 4.27B
+8.85%-17.60%-20.67%+23.50% 3.2B
-2.25%+0.64%+11.18%+51.16% 2.82B
+1.95%-3.11%-7.80%-4.20% 2.13B
Average +0.72%+0.09%+36.94%+20.65% 48.43B
Weighted average by Cap. -1.59%+11.09%+63.62%+30.23%

Financials

2026 *2027 *
Net sales 472M 404M 377M 346M 650M 45.12B 662M 4.47B 1.74B 22.61B 1.77B 1.73B 74.87B 494M 423M 395M 362M 680M 47.26B 694M 4.68B 1.82B 23.68B 1.85B 1.81B 78.41B
Net income 203M 174M 162M 149M 280M 19.45B 285M 1.93B 751M 9.75B 763M 747M 32.27B 220M 188M 176M 161M 303M 21.04B 309M 2.08B 812M 10.54B 826M 808M 34.91B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
21/08/26 $4.140 -5.05% 1,470,898
19/08/26 $4.360 +1.16% 1,478,134
18/08/26 $4.310 -1.15% 1,411,493
17/08/26 $4.360 +1.16% 1,377,034
14/08/26 $4.310 +5.64% 2,334,027
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.360USD
Average target price
6.100USD
Spread / Average Target
+39.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock